JP2008503588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503588A5 JP2008503588A5 JP2007518209A JP2007518209A JP2008503588A5 JP 2008503588 A5 JP2008503588 A5 JP 2008503588A5 JP 2007518209 A JP2007518209 A JP 2007518209A JP 2007518209 A JP2007518209 A JP 2007518209A JP 2008503588 A5 JP2008503588 A5 JP 2008503588A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- oxy
- naphthalenyl
- methyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 208000014311 Cushing syndrome Diseases 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 206010020112 Hirsutism Diseases 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 230000035876 healing Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- WLCNMXHJDTTWKE-OVCLIPMQSA-N (e)-3-[4-(3-cyclopropyl-6-hydroxy-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1OC(C1=CC=C(O)C=C1C=C1C2CC2)=C1C1=CC=CC=C1 WLCNMXHJDTTWKE-OVCLIPMQSA-N 0.000 claims 2
- ASLLTCBMLQIHGX-UXBLZVDNSA-N (e)-3-[4-[2-(3-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound C=1C=CC(F)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C(C(F)(F)F)=C1 ASLLTCBMLQIHGX-UXBLZVDNSA-N 0.000 claims 2
- QHFFNVFDURTHPH-UHFFFAOYSA-N 1-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxybenzoyl]piperidine-4-carboxylic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC(C=C1)=CC=C1C(=O)N1CCC(C(O)=O)CC1 QHFFNVFDURTHPH-UHFFFAOYSA-N 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- -1 6-hydroxy-3-octyl-2-phenyl-1-naphthalenyl Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006298 Breast pain Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010054089 Depressive symptom Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010020564 Hyperadrenocorticism Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000006662 Mastodynia Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010029216 Nervousness Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039792 Seborrhoea Diseases 0.000 claims 2
- 208000030047 Sexual desire disease Diseases 0.000 claims 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 201000002996 androgenic alopecia Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000037182 bone density Effects 0.000 claims 2
- 230000008468 bone growth Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 230000037152 sensory function Effects 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 238000005728 strengthening Methods 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 2
- 201000007954 uterine fibroid Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 230000001457 vasomotor Effects 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 230000003313 weakening effect Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- WTFDOJISMRWHQM-XYOKQWHBSA-N (e)-3-[3-fluoro-4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1F WTFDOJISMRWHQM-XYOKQWHBSA-N 0.000 claims 1
- LYWRTXURSKLWCG-KNTRCKAVSA-N (e)-3-[4-(3-butyl-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CCCC)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 LYWRTXURSKLWCG-KNTRCKAVSA-N 0.000 claims 1
- VQVMRAKFGMGHHR-SFQUDFHCSA-N (e)-3-[4-(3-butyl-6-hydroxy-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CCCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 VQVMRAKFGMGHHR-SFQUDFHCSA-N 0.000 claims 1
- AZPGNKDUKORKGR-LFIBNONCSA-N (e)-3-[4-(3-ethyl-6-hydroxy-2-phenylnaphthalen-1-yl)oxyphenyl]-1-(4-methylpiperazin-1-yl)prop-2-en-1-one Chemical compound C=1C=CC=CC=1C=1C(CC)=CC2=CC(O)=CC=C2C=1OC(C=C1)=CC=C1\C=C\C(=O)N1CCN(C)CC1 AZPGNKDUKORKGR-LFIBNONCSA-N 0.000 claims 1
- FVUBUWFLABJVSN-XNTDXEJSSA-N (e)-3-[4-(3-ethyl-6-hydroxy-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 FVUBUWFLABJVSN-XNTDXEJSSA-N 0.000 claims 1
- STFVACMLCYEGAI-WYMLVPIESA-N (e)-3-[4-(3-methyl-2-phenylnaphthalen-1-yl)oxy-2-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C(C(F)(F)F)=C1 STFVACMLCYEGAI-WYMLVPIESA-N 0.000 claims 1
- DQJWKODHBZCCTI-DTQAZKPQSA-N (e)-3-[4-(3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 DQJWKODHBZCCTI-DTQAZKPQSA-N 0.000 claims 1
- QQUPEUXIWPAGSG-XNTDXEJSSA-N (e)-3-[4-(6-hydroxy-2-phenyl-3-propan-2-ylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C(C)C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 QQUPEUXIWPAGSG-XNTDXEJSSA-N 0.000 claims 1
- LBICCYGQGHMEMC-LFIBNONCSA-N (e)-3-[4-(6-hydroxy-2-phenyl-3-propylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 LBICCYGQGHMEMC-LFIBNONCSA-N 0.000 claims 1
- PEXWXIREBCKWGB-XYOKQWHBSA-N (e)-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxy-2-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C(C(F)(F)F)=C1 PEXWXIREBCKWGB-XYOKQWHBSA-N 0.000 claims 1
- SAAUQOWAAWXEGD-XYOKQWHBSA-N (e)-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxy-3-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1C(F)(F)F SAAUQOWAAWXEGD-XYOKQWHBSA-N 0.000 claims 1
- RQNIQHCKYKUMHB-SFQUDFHCSA-N (e)-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]-1-piperidin-1-ylprop-2-en-1-one Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC(C=C1)=CC=C1\C=C\C(=O)N1CCCCC1 RQNIQHCKYKUMHB-SFQUDFHCSA-N 0.000 claims 1
- AUURCJRXNDZHEQ-QGOAFFKASA-N (e)-3-[4-(6-hydroxy-3-pentyl-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CCCCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 AUURCJRXNDZHEQ-QGOAFFKASA-N 0.000 claims 1
- KHBCBMPQYHJXBB-SDNWHVSQSA-N (e)-3-[4-(7-fluoro-6-hydroxy-2-phenyl-3-propylnaphthalen-1-yl)oxyphenyl]prop-2-enamide Chemical compound C=1C=CC=CC=1C=1C(CCC)=CC2=CC(O)=C(F)C=C2C=1OC1=CC=C(\C=C\C(N)=O)C=C1 KHBCBMPQYHJXBB-SDNWHVSQSA-N 0.000 claims 1
- DEMGEYANMMWDMY-SDNWHVSQSA-N (e)-3-[4-(7-fluoro-6-hydroxy-2-phenyl-3-propylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CCC)=CC2=CC(O)=C(F)C=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 DEMGEYANMMWDMY-SDNWHVSQSA-N 0.000 claims 1
- JFXZWQHUFXHIDN-NTUHNPAUSA-N (e)-3-[4-[2-(4-fluorophenyl)-6-hydroxy-3-propylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C=1C=C(F)C=CC=1C=1C(CCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(N)=O)C(C(F)(F)F)=C1 JFXZWQHUFXHIDN-NTUHNPAUSA-N 0.000 claims 1
- WQBXNHUTYLSZQV-NTUHNPAUSA-N (e)-3-[4-[2-(4-fluorophenyl)-6-hydroxy-3-propylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(CCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C(C(F)(F)F)=C1 WQBXNHUTYLSZQV-NTUHNPAUSA-N 0.000 claims 1
- BNHIPEWSUXLFAB-NTCAYCPXSA-N (e)-3-[4-[2-phenyl-3-(trifluoromethyl)naphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1OC(C1=CC=CC=C1C=C1C(F)(F)F)=C1C1=CC=CC=C1 BNHIPEWSUXLFAB-NTCAYCPXSA-N 0.000 claims 1
- GPFIKCYCCKWZTJ-DTQAZKPQSA-N (e)-3-[4-[3-(methoxymethyl)-2-phenylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(COC)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 GPFIKCYCCKWZTJ-DTQAZKPQSA-N 0.000 claims 1
- MDBIUAHKJNWVHH-WOJGMQOQSA-N (e)-3-[4-[3-butyl-2-(4-fluorophenyl)naphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(CCCC)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 MDBIUAHKJNWVHH-WOJGMQOQSA-N 0.000 claims 1
- TVYDNXHHJPRCGC-WOJGMQOQSA-N (e)-3-[4-[3-butyl-2-(4-hydroxyphenyl)naphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=C(O)C=CC=1C=1C(CCCC)=CC2=CC=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 TVYDNXHHJPRCGC-WOJGMQOQSA-N 0.000 claims 1
- IFYZGAKDZYSFKD-KPKJPENVSA-N (e)-3-[4-[6-hydroxy-2-(3-hydroxyphenyl)-3-methylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC(O)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 IFYZGAKDZYSFKD-KPKJPENVSA-N 0.000 claims 1
- UYVDOWHIPDFHHB-YIXHJXPBSA-N (e)-3-[4-[6-hydroxy-2-(4-hydroxyphenyl)-3-methylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=C(O)C=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 UYVDOWHIPDFHHB-YIXHJXPBSA-N 0.000 claims 1
- BVPCRBLCJPACOI-MDWZMJQESA-N (e)-3-[4-[6-hydroxy-2-phenyl-3-(3,3,3-trifluoropropyl)naphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1OC1=C(C=2C=CC=CC=2)C(CCC(F)(F)F)=CC2=CC(O)=CC=C12 BVPCRBLCJPACOI-MDWZMJQESA-N 0.000 claims 1
- MMFRVJDOHBKSPA-XNTDXEJSSA-N (e)-3-[4-[6-hydroxy-3-(2-methylpropyl)-2-phenylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(CC(C)C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 MMFRVJDOHBKSPA-XNTDXEJSSA-N 0.000 claims 1
- XTWHAGXCPCKBBX-YIXHJXPBSA-N (e)-3-[4-[7-hydroxy-2-(4-hydroxyphenyl)-3-methylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=C(O)C=CC=1C=1C(C)=CC2=CC=C(O)C=C2C=1OC1=CC=C(\C=C\C(O)=O)C=C1 XTWHAGXCPCKBBX-YIXHJXPBSA-N 0.000 claims 1
- CNAAQGNMWLOZJG-UHFFFAOYSA-N 1,1,1-trifluoro-n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]methanesulfonamide Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(NS(=O)(=O)C(F)(F)F)C=C1 CNAAQGNMWLOZJG-UHFFFAOYSA-N 0.000 claims 1
- YLIHKUHDFDMXSR-UHFFFAOYSA-N 2,2,2-trifluoro-n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]ethanesulfonamide Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(NS(=O)(=O)CC(F)(F)F)C=C1 YLIHKUHDFDMXSR-UHFFFAOYSA-N 0.000 claims 1
- QGUXEUVENJBAIN-UHFFFAOYSA-N 2-[2-[4-(6-methoxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenoxy]ethoxy]ethanol Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(OC)=CC=C2C=1OC1=CC=C(OCCOCCO)C=C1 QGUXEUVENJBAIN-UHFFFAOYSA-N 0.000 claims 1
- CLSWMBJNSWKOAP-UHFFFAOYSA-N 2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenoxy]acetic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(OCC(O)=O)C=C1 CLSWMBJNSWKOAP-UHFFFAOYSA-N 0.000 claims 1
- GPQXRKFBSAAENN-UHFFFAOYSA-N 2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]ethenylphosphonic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=CP(O)(O)=O)C=C1 GPQXRKFBSAAENN-UHFFFAOYSA-N 0.000 claims 1
- PAQRJMRJEDZAOY-UHFFFAOYSA-N 2-[4-[2-(3-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenoxy]acetic acid Chemical compound C=1C=CC(F)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(OCC(O)=O)C(C(F)(F)F)=C1 PAQRJMRJEDZAOY-UHFFFAOYSA-N 0.000 claims 1
- WJXHYQJEWDCTSI-UHFFFAOYSA-N 2-[[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]methylidene]-3-methylbutanoic acid Chemical compound C1=CC(C=C(C(C)C)C(O)=O)=CC=C1OC1=C(C=2C=CC=CC=2)C(C)=CC2=CC(O)=CC=C12 WJXHYQJEWDCTSI-UHFFFAOYSA-N 0.000 claims 1
- TVWVBLBOBZDESR-UHFFFAOYSA-N 2-chloro-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=C(Cl)C(O)=O)C=C1 TVWVBLBOBZDESR-UHFFFAOYSA-N 0.000 claims 1
- YRIKKAKFWXBIPT-UHFFFAOYSA-N 3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyanilino]-3-oxopropanoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(NC(=O)CC(O)=O)C=C1 YRIKKAKFWXBIPT-UHFFFAOYSA-N 0.000 claims 1
- PRWCXNGPHMFYOX-UHFFFAOYSA-N 3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]-2-methylprop-2-enoic acid Chemical compound C1=CC(C=C(C)C(O)=O)=CC=C1OC1=C(C=2C=CC=CC=2)C(C)=CC2=CC(O)=CC=C12 PRWCXNGPHMFYOX-UHFFFAOYSA-N 0.000 claims 1
- RMDIMZDXBFWENB-UHFFFAOYSA-N 3-[4-(6-hydroxy-3-methyl-2-thiophen-3-ylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C1=CSC=C1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=CC(O)=O)C=C1 RMDIMZDXBFWENB-UHFFFAOYSA-N 0.000 claims 1
- CBTPRFAYDIJLHO-UHFFFAOYSA-N 3-[4-(6-methoxy-3-methyl-2-pyridin-4-ylnaphthalen-1-yl)oxyphenyl]prop-2-enoic acid Chemical compound C=1C=NC=CC=1C=1C(C)=CC2=CC(OC)=CC=C2C=1OC1=CC=C(C=CC(O)=O)C=C1 CBTPRFAYDIJLHO-UHFFFAOYSA-N 0.000 claims 1
- UFWFMJAMPSEUDD-UHFFFAOYSA-N 3-[4-[2-(4-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=CC(O)=O)C=C1 UFWFMJAMPSEUDD-UHFFFAOYSA-N 0.000 claims 1
- ADWRMHDPISTSPC-UHFFFAOYSA-N 3-[4-[2-(4-fluorophenyl)-6-hydroxy-3-propylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenyl]-2-methylprop-2-enamide Chemical compound C=1C=C(F)C=CC=1C=1C(CCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=C(C)C(N)=O)C(C(F)(F)F)=C1 ADWRMHDPISTSPC-UHFFFAOYSA-N 0.000 claims 1
- ZCXYUBYHJHMBBE-UHFFFAOYSA-N 3-[4-[2-(4-fluorophenyl)-6-hydroxy-3-propylnaphthalen-1-yl]oxy-2-(trifluoromethyl)phenyl]-2-methylprop-2-enoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(CCC)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=C(C)C(O)=O)C(C(F)(F)F)=C1 ZCXYUBYHJHMBBE-UHFFFAOYSA-N 0.000 claims 1
- SBXVTOHCMFIWKW-UHFFFAOYSA-N 3-[4-[2-(furan-2-yl)-6-methoxy-3-methylnaphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=COC=1C=1C(C)=CC2=CC(OC)=CC=C2C=1OC1=CC=C(C=CC(O)=O)C=C1 SBXVTOHCMFIWKW-UHFFFAOYSA-N 0.000 claims 1
- XCBXMXDJYFUWMH-UHFFFAOYSA-N 3-[4-[6-hydroxy-2-(3-hydroxyphenyl)-3-methylnaphthalen-1-yl]oxyphenyl]propanoic acid Chemical compound C=1C=CC(O)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(CCC(O)=O)C=C1 XCBXMXDJYFUWMH-UHFFFAOYSA-N 0.000 claims 1
- WVXAHVYSACJEMU-UHFFFAOYSA-N 3-[4-[6-hydroxy-2-(4-hydroxyphenyl)-4-methoxy-3-methylnaphthalen-1-yl]oxyphenyl]propanoic acid Chemical compound C=1C=C(CCC(O)=O)C=CC=1OC=1C2=CC=C(O)C=C2C(OC)=C(C)C=1C1=CC=C(O)C=C1 WVXAHVYSACJEMU-UHFFFAOYSA-N 0.000 claims 1
- AHEPWFQGSCASAL-UHFFFAOYSA-N 3-[4-[6-hydroxy-3-methyl-2-[3-(trifluoromethyl)phenyl]naphthalen-1-yl]oxyphenyl]prop-2-enoic acid Chemical compound C=1C=CC(C(F)(F)F)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C=CC(O)=O)C=C1 AHEPWFQGSCASAL-UHFFFAOYSA-N 0.000 claims 1
- FESQLOKYCKAHFL-UHFFFAOYSA-N 3-[4-[7-hydroxy-2-(4-hydroxyphenyl)-3-methylnaphthalen-1-yl]oxyphenyl]propanoic acid Chemical compound C=1C=C(O)C=CC=1C=1C(C)=CC2=CC=C(O)C=C2C=1OC1=CC=C(CCC(O)=O)C=C1 FESQLOKYCKAHFL-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- CUBAKDKRLHVTCC-UHFFFAOYSA-N 4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxybenzoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C(O)=O)C=C1 CUBAKDKRLHVTCC-UHFFFAOYSA-N 0.000 claims 1
- AITCYVMFVXKXDY-UHFFFAOYSA-N 4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxybenzonitrile Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C#N)C=C1 AITCYVMFVXKXDY-UHFFFAOYSA-N 0.000 claims 1
- VOQNEHZEWLQRHR-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxy-2-(trifluoromethyl)benzoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C(O)=O)C(C(F)(F)F)=C1 VOQNEHZEWLQRHR-UHFFFAOYSA-N 0.000 claims 1
- SQZZSZKQACNSOQ-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxybenzoic acid Chemical compound C=1C=C(F)C=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(C(O)=O)C=C1 SQZZSZKQACNSOQ-UHFFFAOYSA-N 0.000 claims 1
- BFQBIEQTTSFAHC-UHFFFAOYSA-N 4-[2-(4-hydroxyphenyl)-3-(trifluoromethyl)naphthalen-1-yl]oxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC(C1=CC=CC=C1C=C1C(F)(F)F)=C1C1=CC=C(O)C=C1 BFQBIEQTTSFAHC-UHFFFAOYSA-N 0.000 claims 1
- LZAUUPGGTANNPB-UHFFFAOYSA-N 4-[4-(6-methoxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenoxy]butanoic acid Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(OC)=CC=C2C=1OC1=CC=C(OCCCC(O)=O)C=C1 LZAUUPGGTANNPB-UHFFFAOYSA-N 0.000 claims 1
- TXDSQFYSWURICA-UHFFFAOYSA-N 5-[4-[2-(2-hydroxyethoxy)ethoxy]phenoxy]-7-methyl-6-phenylnaphthalen-2-ol Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(OCCOCCO)C=C1 TXDSQFYSWURICA-UHFFFAOYSA-N 0.000 claims 1
- MSHZXLCHSGSEPR-UHFFFAOYSA-N 6-(3-fluorophenyl)-5-[4-(2-hydroxyethoxy)-3-(trifluoromethyl)phenoxy]-7-methylnaphthalen-2-ol Chemical compound C=1C=CC(F)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(OCCO)C(C(F)(F)F)=C1 MSHZXLCHSGSEPR-UHFFFAOYSA-N 0.000 claims 1
- MTMMKTPVXPGNTG-UHFFFAOYSA-N 6-(3-fluorophenyl)-5-[4-[2-(2-hydroxyethoxy)ethoxy]-3-(trifluoromethyl)phenoxy]-7-methylnaphthalen-2-ol Chemical compound C=1C=CC(F)=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(OCCOCCO)C(C(F)(F)F)=C1 MTMMKTPVXPGNTG-UHFFFAOYSA-N 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000004217 heart function Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- HYGPGVMCMDLCPZ-UHFFFAOYSA-N methyl 4-[2-(3-fluorophenyl)-6-hydroxy-3-methylnaphthalen-1-yl]oxy-2-(trifluoromethyl)benzoate Chemical compound C1=C(C(F)(F)F)C(C(=O)OC)=CC=C1OC1=C(C=2C=C(F)C=CC=2)C(C)=CC2=CC(O)=CC=C12 HYGPGVMCMDLCPZ-UHFFFAOYSA-N 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- KUVIPQATPJRYDB-UHFFFAOYSA-N n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxy-2-(trifluoromethyl)phenyl]methanesulfonamide Chemical compound C=1C=CC=CC=1C=1C(C)=CC2=CC(O)=CC=C2C=1OC1=CC=C(NS(C)(=O)=O)C(C(F)(F)F)=C1 KUVIPQATPJRYDB-UHFFFAOYSA-N 0.000 claims 1
- IVRDJNWMENZMBA-UHFFFAOYSA-N n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxy-2-methylphenyl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(C)=CC(OC=2C3=CC=C(O)C=C3C=C(C)C=2C=2C=CC=CC=2)=C1 IVRDJNWMENZMBA-UHFFFAOYSA-N 0.000 claims 1
- HNJHRVFRZGVZKL-UHFFFAOYSA-N n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=C1)=CC=C1OC1=C(C=2C=CC=CC=2)C(C)=CC2=CC(O)=CC=C12 HNJHRVFRZGVZKL-UHFFFAOYSA-N 0.000 claims 1
- ZOIWTYSITHYFAL-UHFFFAOYSA-N n-[4-(6-hydroxy-3-methyl-2-phenylnaphthalen-1-yl)oxyphenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1OC1=C(C=2C=CC=CC=2)C(C)=CC2=CC(O)=CC=C12 ZOIWTYSITHYFAL-UHFFFAOYSA-N 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 230000035946 sexual desire Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58191304P | 2004-06-22 | 2004-06-22 | |
| PCT/US2005/021963 WO2006002185A1 (en) | 2004-06-22 | 2005-06-21 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503588A JP2008503588A (ja) | 2008-02-07 |
| JP2008503588A5 true JP2008503588A5 (cg-RX-API-DMAC7.html) | 2008-06-19 |
Family
ID=35124373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518209A Pending JP2008503588A (ja) | 2004-06-22 | 2005-06-21 | 化学化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7649093B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1773750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008503588A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070026841A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101006042A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005258085A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0512395A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2571309A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL180067A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA28725B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06015152A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20070379L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2352555C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006002185A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200610782B (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2738878C (en) * | 2008-09-29 | 2013-08-13 | Eli Lilly And Company | Selective estrogen receptor modulator for the treatment of osteoarthritis |
| CN101863769B (zh) * | 2010-05-06 | 2013-08-07 | 中科院广州化学有限公司 | 一种1-四氢萘酮衍生物的合成方法 |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| CN110156838A (zh) * | 2013-05-14 | 2019-08-23 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
| CN105777654B (zh) * | 2016-03-28 | 2018-03-27 | 贵州大学 | 一种含喹唑啉的阿魏酸酯类衍生物、其制备方法和用途 |
| US11718791B2 (en) | 2017-03-09 | 2023-08-08 | Merck Patent Gmbh | Polymerisable compounds and the use thereof in liquid-crystal displays |
| SG11202006942WA (en) * | 2018-01-22 | 2020-08-28 | Radius Pharmaceuticals Inc | Estrogen receptor-modulating compounds |
| CN114133336B (zh) * | 2020-09-03 | 2024-04-02 | 沈阳药科大学 | 4-甲氧基萘取代的苯胺类化合物及其制备方法和应用 |
| TWI896926B (zh) * | 2022-01-21 | 2025-09-11 | 大陸商上海海和藥物研究開發股份有限公司 | 膦酸類化合物及其前藥、它們的製備方法及用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719043B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés bicycliques-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
| ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
| US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| CA2217810A1 (en) * | 1996-10-10 | 1998-04-10 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods |
| US5929090A (en) * | 1997-09-12 | 1999-07-27 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods |
| EA008024B1 (ru) * | 2002-07-22 | 2007-02-27 | Эли Лилли Энд Компани | Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу |
| EP1727802A1 (en) * | 2004-02-25 | 2006-12-06 | Smithkline Beecham Corporation | Substituted quinoline compounds for use as selective estrogen receptor modulator |
-
2005
- 2005-06-21 CA CA002571309A patent/CA2571309A1/en not_active Abandoned
- 2005-06-21 KR KR1020077001571A patent/KR20070026841A/ko not_active Withdrawn
- 2005-06-21 CN CNA2005800285575A patent/CN101006042A/zh active Pending
- 2005-06-21 AU AU2005258085A patent/AU2005258085A1/en not_active Abandoned
- 2005-06-21 EP EP05760839A patent/EP1773750A1/en not_active Withdrawn
- 2005-06-21 MX MXPA06015152A patent/MXPA06015152A/es not_active Application Discontinuation
- 2005-06-21 JP JP2007518209A patent/JP2008503588A/ja active Pending
- 2005-06-21 BR BRPI0512395-0A patent/BRPI0512395A/pt not_active IP Right Cessation
- 2005-06-21 US US11/570,838 patent/US7649093B2/en not_active Expired - Fee Related
- 2005-06-21 WO PCT/US2005/021963 patent/WO2006002185A1/en not_active Ceased
- 2005-06-21 RU RU2006145200/04A patent/RU2352555C2/ru not_active IP Right Cessation
-
2006
- 2006-12-14 IL IL180067A patent/IL180067A0/en unknown
- 2006-12-20 ZA ZA200610782A patent/ZA200610782B/xx unknown
- 2006-12-28 MA MA29570A patent/MA28725B1/fr unknown
-
2007
- 2007-01-19 NO NO20070379A patent/NO20070379L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503588A5 (cg-RX-API-DMAC7.html) | ||
| JP2007500705A5 (cg-RX-API-DMAC7.html) | ||
| RU2006145200A (ru) | Химические соединения | |
| JP5299810B2 (ja) | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 | |
| ES2240558T3 (es) | Derivados de tiazol y oxazol como activadores de receptores activados por el proliferador de peroxisoma humano. | |
| JP2008500991A (ja) | 医学的使用のためのｃｒｔｈ２レセプターリガンド | |
| JP2004520292A5 (cg-RX-API-DMAC7.html) | ||
| US20030207924A1 (en) | Compounds that modulate PPAR activity and methods of preparation | |
| JP2009528296A5 (cg-RX-API-DMAC7.html) | ||
| JP2012521406A5 (cg-RX-API-DMAC7.html) | ||
| SK1962001A3 (en) | Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators | |
| JP2004514668A (ja) | ３−アロイルインドール誘導体およびｃｂ２レセプターアゴニストとしてのそれらの使用 | |
| CN1283183A (zh) | 具有mmp和tnf抑制活性的异羟肟酸和羧酸衍生物 | |
| CA2533812A1 (en) | Substituted cycloalkylidene compounds | |
| HUP0400837A2 (hu) | 2-feniltiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2010513283A5 (cg-RX-API-DMAC7.html) | ||
| JP2007511485A (ja) | Ｐｐａｒアゴニストとしての置換ピラゾール | |
| JP2013526494A5 (cg-RX-API-DMAC7.html) | ||
| JP2005509632A5 (cg-RX-API-DMAC7.html) | ||
| JP2007500700A5 (cg-RX-API-DMAC7.html) | ||
| JP2011513383A (ja) | 新規なアミノメチルベンゼン誘導体 | |
| JP2007523952A5 (cg-RX-API-DMAC7.html) | ||
| JP2004517100A (ja) | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール | |
| CN1396915A (zh) | 新的杂环衍生物、其制备方法和包含它们的药物组合物 | |
| JP2008545699A5 (cg-RX-API-DMAC7.html) |